ENDS US 2017 Speakers

  • John Bellinger

    Chief Technologist and Co-Owner Evolv

    John Bellinger is 50% owner and Chief Technologist of Evolv, the largest domestic manufacturer of E-cigarette control electronics. Founded in 2010, Evolv produces over 1,000,000 e-cigarette circuit boards per year from its Hudson, Ohio plant. Evolv’s DNA family of products can be found powering the high-end electronic cigarette products of dozens of domestic and foreign manufacturers.

    Evolv was the first company to offer directly wattage controlled electronic cigarettes in 2010. In 2014 Evolv released the first e-cigarette products able to directly sense, limit and control the temperature of the heating coil. John has personally designed or led the design team for all 21 of Evolv’s electronic cigarette controller families.

    Evolv has granted and pending patents related to electronic cigarette control and safety. John is listed as the first named inventor on all of Evolv’s patent submissions to date.

    John’s controller designs feature built in chargers and include software and hardware protection of the battery via: charge rate monitoring, temperature monitoring, charge voltage monitoring, discharge rate monitoring, short circuit protection, reverse voltage protection, protection against battery overloading, fusing, multi-cell balancing and battery management systems.

    John is the Principal Investigator for Evolv’s SBIR Grant N43DA150072 to develop a research-focused reference electronic cigarette for the National Institute on Drug Abuse.  Phase I of this project is complete and Evolv is presently developing its Phase II proposal.

    Evolv is committed to the PMTA process and has begun filing Tobacco Product Master Files for its controller products. Evolv intends to submit PMTA applications on several complete systems by 2019. In addition, Evolv is assisting its customers with FDA premarket applications. 

    Evolv is TAG administrator for ANSI/ISO TC 126 Subchapter 3 which covers vapor products and vapor product standards.  John is the interim leader for the Systems working group.

    John has spoken on e-cigarette technology, safety advances and the need for product standards to industry groups as well as the FDA and the National Academy of Science. He has served both as a presenter and as a panelist at industry events including TMA and GTNF.

    John holds a B.S in Mechanical Engineering from Carnegie Mellon University. 

  • Autumn Bernal

    Senior Health Scientist Cardno ChemRisk

    Dr. Autumn Bernal is a Supervising Health Scientist with Cardno ChemRisk. Her principal areas of training and expertise include human health risk assessment and toxicology.  Dr. Bernal’s expertise includes characterizing potential consumer exposures and health effects from use of electronic nicotine delivery systems, including analyses of user topography data, quantification of various aerosol constituents, and designing non-clinical studies.  Dr. Bernal completed her Ph.D. in Genetics and Integrated Toxicology at Duke University, where she examined the potential health effects of early developmental nutritional and physical exposures.

  • Azim Chowdhury

    Partner Keller and Heckman LLP

    Azim Chowdhury practices food, tobacco and e-vapor law in the Washington, D.C. office of Keller and Heckman LLP. Mr. Chowdhury advises domestic and foreign corporations in matters of Food and Drug Administration (FDA) and international regulatory compliance. In particular, he assists corporations in establishing clearances for food and drug additives in the U.S., Canada, and European Union, with an emphasis on indirect additives used in food-contact materials. Mr. Chowdhury has also developed expertise in tobacco product regulation and spearheaded the Tobacco and E-Vapor practice at Keller and Heckman. Specifically, Mr. Chowdhury has experience representing tobacco and electronic vapor product (e-cigarette) manufacturers, suppliers, and trade associations in matters of FDA regulatory and corporate compliance. He is also a frequent contributor to the Tobacco Reporter and the Food and Drug Law Institute’s Update magazine; edited and co-authored FDLI’s tobacco regulation manuals, Tobacco Regulation and Compliance: An Essential Resource and Tobacco and Nicotine Delivery: Regulation and Compliance, 2nd Edition; and previously served on the Editorial Advisory Board of the Food and Drug Law Journal.  Prior to entering private practice, he served as a judicial law clerk on the Court of Special Appeals of Maryland.  Mr. Chowdhury received a B.A. and B.S. from Johns Hopkins University, a MBA from the University of Maryland Robert H. Smith School of Business, and a JD, cum laude, from the University of Maryland School of Law.

  • Gregory Conley

    President American Vaping Association

    Gregory Conley is the president of the American Vaping Association (AVA), a nonprofit organization that champions regulatory policies toward vapor products designed to maximize the effectiveness of vaping for quitting smoking. He is one of the most prominent defenders of vaping in the United States and has appeared on CNN, Fox News, and MSNBC. In addition to his work with the AVA, Mr. Conley is an attorney and a consultant on vaping legislative and regulatory issues. He began working on vaping issues in 2010 after quitting smoking with a vapor product while in law school. He served as the pro bono legislative director for the Consumer Advocates for Smoke-Free Alternatives Association from 2011 to 2014. 

  • Linda Crumpler

    Business Development Director Cerulean

    Linda Crumpler is the business development director for Cerulean, a leading manufacturer of precision test and measuring equipment to the tobacco industry, headquartered in Milton Keynes, England.

    Crumpler holds degrees in chemistry, medical technology and human resources. She also is a certified ISO 17025 lead auditor. Crumpler joined R.J. Reynolds Tobacco Co. in 1979 and throughout her tenure there held many positions, including senior director of tobacco and smoke chemistry and senior director of regulatory compliance.

    Crumpler joined Cerulean in 2008, first in a consultancy role and in 2010 as the business development director.

    Crumpler has served several terms on the Coresta scientific commission on both the smoke science and product technology study groups. Since 1995, she has been active in Coresta taskforces and subgroups, such as the side-stream task force, low-ignition propensity task force and the sub-committee on harmonization of carbon monoxide yields.

    Currently she serves as chair of the routine analytical chemistry sub-group and is a member and contributor to the special analytes sub-group, the smokeless sub-group, and the e-cigarette task force.

    Crumpler also serves as a technical expert on several ISO committees, and was recognized as a 2015 Professional Woman of the Year by the National Association of Professional Women.

  • Brittani Cushman

    Vice President of External Affairs Turning Point Brands, Inc.

    Brittani Cushman is the Vice President of External Affairs for Turning Point Brands, parent company of National Tobacco Company, VaporBeast, Vapor Shark, and Intrepid Brands, of Louisville, Kentucky. Ms. Cushman is responsible for the management of regulatory and legislative issues at both the federal and state levels. Ms. Cushman provides industry leadership among like-sized manufacturers, advising on regulatory issues as they emerge and placing those issues in the context of both the current science and complex landscape of the vaping and tobacco industries. Ms. Cushman currently serves on the National Association of Tobacco Outlets (NATO) Board of Directors, the Vapor Technology Association (VTA) Board of Directors, and the Pipe Tobacco Council Board of Directors. She also participates in the Cigar Association of America and the Coalition of Independent Tobacco Manufacturers of America (CITMA).

    Ms. Cushman has a B.S.B.A. in Business Management from The University of Tulsa and a J.D. from Washington & Lee University School of Law. She previously served as General Counsel for a privately-held tobacco product manufacturer.

  • Charles Ducker

    Principal Chemist/Group Leader Eurofins Medical Device Testing

    Dr. Charles Ducker is a Principal Chemist/Group Leader for Eurofins Medical Device Testing Extractables and Leachables group where he performs extractables and leachables testing using LC/MS-TOF, LC/MS/MS, GC/MS, and ICP-OES technology. Specializing in LC/MS analysis, Dr. Ducker has 13 years of experience in the biotech industry and has served as the lead scientist for two significant drug discovery programs. Dr. Ducker earned a Ph.D. in Biochemistry/Molecular Biology from The Pennsylvania State University, as well as a B.S. in Biology from Millersville University.

  • Dr. Ian M. Fearon

    Senior Director Clinical and Regulatory Affairs EMEA JUUL Labs

    Ian is a Senior Director Clinical and Regulatory Affairs EMEA at JUUL Labs. He specializes in the biological and psychological effects of nicotine, clinical studies to assess the biological effects of electronic cigarettes and tobacco heating devices, and the scientific basis for regulation.  Prior to joining JUUL, Ian was Principal Scientist and Head of Clinical Research at British American Tobacco's central research and development center in Southampton, U.K. Prior to joining BAT in 2008, he pursued an academic career as a Lecturer in Physiology at the University of Manchester and an Assistant Professor at McMaster University in Hamilton, Canada.  Ian is a highly-cited scientific researcher and writer, contributing to more than 50 peer-reviewed papers and book chapters and generating over 1,900 citations.

  • David Graham

    Chief Impact Officer NJOY

    David Graham is Chief Impact Officer at NJOY, a role which leads efforts across the company to maximize the positive impact on public health of the company’s products and services through increasing their reach and effectiveness while including oversight of regulatory affairs for the company. He has extensive experience in nicotine and non-nicotine new product development, tobacco control policy, and related regulation in the international healthcare and e-vapor industries spanning ~ 25 years. Beginning with nicotine replacement therapy (NRT)/smoking cessation products in the UK in 1992, followed by International product and category development roles in Sweden, he moved to the USA in 2000 with Pharmacia, subsequently becoming part of Pfizer and then moving to Johnson & Johnson.

    In 2013, he joined NJOY to lead the regulatory affairs, quality & compliance function for the company and prepare for regulation by FDA and other regulatory agencies in the US and abroad. In addition to multiple interactions with FDA, and other regulatory agencies internationally, David co-led NJOY’s engagement with the National Institute of Drug Abuse (NIDA) on its Small Business Innovation Research (SBIR) award for NJOY to develop an Electronic Nicotine Delivery System (ENDS) for use for clinical research in smoking cessation, leading to the establishment of the first FDA Drug Master File (DMF) for ENDS products. In late 2016, David co-founded and was President of Reveritas Group, a multi-partner consultancy firm of specialists and preferred providers formed to aid ENDS companies navigate all aspects of FDA’s Premarket Tobacco Application (PMTA) process via a total programming approach, and/or provide select outsourced resources as required. Following FDA’s extension of the PMTA compliance deadline, David returned to NJOY in August 2017 in his current role.

    David is a graduate of Columbia University with a Master’s in Public Policy & Administration.

  • Chris Howard

    Vice President, General Counsel and Chief Compliance Officer E-Alternative Solutions, LLC

    Chris Howard is Vice President, General Counsel and Chief Compliance Officer for E-Alternative Solutions, LLC, a marketer and distributor of vapor products and sister company to Swisher International, based in Jacksonville, Florida.  Mr. Howard is responsible for overseeing EAS’s legal activities and policies, as well as compliance, regulatory affairs and brand protection.  Mr. Howard provides industry leadership among vapor manufacturers and distributors in light of both a rapidly evolving regulatory landscape of the vaping industry and the developing science globally with respect to the vapor category.  Mr. Howard also currently serves on the Vapor Technology Association Board of Directors. 

    Previously, Mr. Howard was General Counsel and Chief Compliance Officer for Fontem Ventures, the manufacturer of blu eCigs products, and he has also held senior legal positions with Lorillard Tobacco Company and ITG Brands, LLC.  During his tenure in these positions, Mr. Howard had primary responsibility for managing complex legal and regulatory issues related to both the tobacco and vaping industries.  He has also served as lead counsel for a division of a global agricultural chemical company and worked on a trial team for a law firm defending product liability litigation against a tobacco product manufacturer.

    Mr. Howard is a frequent speaker on marketing issues and other trends related to the vapor industry.  He has a B.B.A. in Business Management and Marketing from James Madison University and a J.D. from The T.C. Williams School of Law at University of Richmond. 

  • Ian Jones

    Reduced-Risk Products Vice President Japan Tobacco International

    Ian Jones is Japan Tobacco International’s (JTI) reduced-risk products vice president. He is based in Geneva, Switzerland. Jones joined JTI in 2006 from the University of Bath in the U.K., where he was a lecturer in developmental neuroscience in the department of biology and biochemistry.

    Prior to this, he held postdoctoral research positions at the universities of Bath, Oxford and London, specializing in the anatomical neuropharmacology of nicotinic acetylcholine receptors. Jones holds a doctorate in cell physiology, completed at Imperial College London (1995).

  • Patricia I. Kovacevic

    General Counselor and Chief Compliance Officer Consultant Independent Consultant

    A global legal and compliance industry expert Patricia I. Kovacevic’s experience comprises general counsel and chief compliance officer roles at Nicopure Labs LLC, and leading senior legal and compliance positions at, among others, Philip Morris International and Lorillard. Prior to joining Lorillard she was a partner at Patton Boggs. Her expertise includes global e-cigarette and tobacco regulation, compliance and all regulatory aspects of marketing/media communications, corporate affairs, criminal investigations, FCPA, trade sanctions, privacy, product development and launch. Kovacevic served on the board of directors of the Vapor Technology Association and on the advisory board of the Global Tobacco & Nicotine Forum. In the past she was a United Nations staff member, served on the U.N.’s Public-Private Partnership Commission and was also an adviser to the Council for Burley Tobacco. Kovacevic is admitted to practice in New York and before the Supreme Court of the United States. She holds a J.D. from Columbia Law School in New York and has completed the Harvard Business School “Corporate Leader” course. She is fluent in seven European languages. 

  • Amy Madl

    Senior Principal Health Scientist Cardno ChemRisk

    Dr. Amy Madl is a Senior Principal Health Scientist with Cardno ChemRisk.  She has a M.S. and Ph.D. in Pharmacology and Toxicology, is a Diplomate of the American Board of Toxicology (DABT), and has focused her academic and consulting experience in the field of inhalation toxicology.  She has nearly 20 years of experience in the sampling and analysis, toxicology, exposure, and risk assessment of airborne chemicals.  Dr. Madl also holds an adjunct position as a Research Associate with the University of California, Davis, where she has served as a co-investigator on multidisciplinary research teams for inhalation research studies.  Her expertise also includes methods for characterization of electronic nicotine delivery systems, including aerosol chemistry and toxicology, consumer exposures, toxicology and pharmacokinetic studies, and human health risk assessments.  Dr. Madl has published over 75 abstracts, book chapters, and peer-reviewed papers on various exposure, toxicology, and risk-related topics.

  • Willie McKinney

    Vice President Regulatory Sciences Altria Client Services

    Willie J. McKinney, Ph.D., D.A.B.T., serves as Vice President, Regulatory Sciences, for Altria Client Services (ALCS) in Richmond, Virginia. In this role, he leads a team that develops scientific evaluation and regulatory science strategies for Altria's family of companies.

    Dr. McKinney has held a variety of positions with increasing responsibilities within the Altria family of companies. He served as Senior Director, Product Integrity and Regulatory Reporting, where he led a team that develops scientific evaluation and regulatory submission strategies for Altria's family of companies; Director, Strategic Product Planning, where he provided operational and strategic support; Senior Manager, Cellular & Molecular Biology Group; and as a visiting scientist at the Institute for Biologische Forschung GmbH (INBIFO) in Köln, Germany.

    Before joining the Altria family of companies in 1998, Dr. McKinney held a variety of academic and research roles, including working as an Associate Research Scientist, Nelson Institute of Environmental Medicine, NYU Medical Center, Tuxedo, N.Y., and as a Graduate Research Assistant at the Center for Environmental Medicine and Lung Biology at the University of North Carolina at Chapel Hill. He also held Toxicology Intern and Research Assistant roles with several government agencies. Dr. McKinney is board certified in Toxicology by the American Board of Toxicology. He has published numerous professional articles related to his research and work, and has presented before various scientific organizations. He holds a BS degree in Biology from Xavier University, an MS in Biology from North Carolina Central University, and a PhD in Environmental Toxicology from the University of North Carolina at Chapel Hill. He serves on the Higher Achievement Board and on the Richmond Higher Achievement Advisory Board.

  • Jose Luis Murillo

    Vice President​ Regulatory Affairs Altria Client Services LLC

    Joe Murillo serves as Vice President, Regulatory Affairs, Altria Client Services. Joe leads FDA-related regulatory strategy, engagement, communications and advocacy for Altria’s tobacco operating companies.  Joe also develops regulatory and research strategies related to Altria’s pursuit of tobacco harm reduction and FDA authorization of modified risk tobacco products.

    Before being appointed to his current position, Joe served as President and General Manager of Nu Mark, LLC. In that role, Joe led the company’s development and marketing of innovative tobacco products for adult tobacco consumers.

    Previously, Joe was Vice President and Associate General Counsel of Altria Client Services, where he led the company’s Brand Integrity efforts and provided legal support to a number of different areas at Altria.  During the course of his career, Joe has developed extensive knowledge of the marketing, sales, distribution, regulatory and communications aspects of bringing tobacco products to market.

    Joe is a 1986 graduate of Columbia Law School and a 1983 graduate of the University of Miami, where he was elected to Phi Beta Kappa.

  • Glenn J. Myatt, Ph.D.

    Chief Scientific Officer Leadscope

    Dr. Myatt is one of the founders and is currently the Chief Scientific Officer of Leadscope, Inc. He has over 25 years of experience researching and developing in silico solutions. He is currently the principal investigator on two US National Institutes of Health research grants and has co-authored 21 publications (including a number of papers related to ICH M7), three books as well as five book chapters.

  • Dr. Daniel Norwood

    Executive Partner SCIO Analytical & Senior Consultant at Smithers Rapra

    Dr. Daniel Norwood joined SCIO Analytical as Executive Partner in June 2015. Prior to SCIO Analytical, Dr. Norwood was a key technical employee at Boehringer Ingelheim Pharmaceuticals where he was successful in various pharmaceutical development roles, including Director Physical and Chemical Analysis.  In June 2015, Dr. Norwood retired with the title of Distinguished Research Fellow in Analytical Development.  Prior to joining Boehringer Ingelheim, Dr. Norwood, with Dr. Feinberg, founded the Structural Chemistry Group at Magellan Laboratories, later Catalent Pharma Solutions, which became widely recognized for its work in pharmaceutical impurity structure elucidation, and in leachables and extractables characterization. Prior to Magellan, he was a pharmaceutical development scientist at the Glaxo Research Institute.  

    Dr. Norwood is an internationally recognized expert in the field of leachables and extractables assessment in pharmaceutical development and manufacturing.  He served as chair of the widely-quoted Product Quality Research Institute (PQRI) Working Group on leachables and extractables in inhalation drug products. He is also a member of the PQRI Working Group on leachables and extractables in parenteral and ophthalmic drug products (PODP), and has served on various technical teams of the International Pharmaceutical Aerosol Consortium on Regulations and Science (IPAC-RS). Since 2010, he has served as a member of the USP Expert Committee on Packaging, Storage and Distribution where he chairs the subcommittee on extractables and leachables. Dr. Norwood has received several industry awards, including the CEO’s Award from Glaxo (1994), the President’s Award from Boehringer Ingelheim (2007), the Excellence in Research Award from PQRI (2009), and the Award for an Innovative Response to Public Health Challenges from USP (2013). Dr. Norwood completed his bachelor’s degree in Biochemistry at Virginia Tech and his doctorate degree in Environmental Chemistry at the University of North Carolina at Chapel Hill, School of Public Health.

  • Tim Phillips

    Managing Director ECigIntelligence

    Tim is founder and managing director of ECigIntelligence.  He is a UK-qualified attorney, having worked at the European Commission, BSkyB and Herbert Smith (an international law firm), AOL Europe, as director of public affairs at Betfair (IPO in 2010 valued at £1.5bn), and as a partner in a New York VC-funded startup in the diamond sector. Tim holds a Postgraduate Diploma in Legal Practise from the University of Law, London and a Masters in Geology from Oxford University.

  • Christopher Russell

    Senior Research Fellow, Behavioural Studies of Tobacco and Nicotine Use Centre for Substance Use Research (CSUR)

    Christopher Russell (Ph.D.) is a behavioural psychologist and senior research fellow at the Centre for Substance Use Research (CSUR), Glasgow, Scotland. Dr Russell leads the Centre’s behavioural studies of tobacco and nicotine use in the United Kingdom and United States.

    Dr Russell conducts pre-market and post-market behavioural studies that aim to characterise the likely impact of marketing specific vapor products on tobacco use behaviour among current, former and never smokers. Through cross-sectional and longitudinal surveys, Dr Russell models the prevalence of different chronologies of initiation, cessation and re-initiation of cigarette smoking and e-cigarette use within large cohorts of adult vapers, and identifies patterns of e-cigarette use that are associated with successful and unsuccessful attempts to switch from smoking to vaping. Most recently, Dr Russell’s 2016 U.S. Vapers Survey obtained data on the vaping devices, flavors and nicotine strengths being used by 15,807 adult frequent vapers in the United States to switch completely from smoking to vaping. Dr Russell is also leading studies of U.S. nationally representative samples of current, former and never smokers who are also never-vapers to assess the role of perceptions of product attractiveness, health risk, and addiction risk as predictors of intentions to begin using specific vapor products.

    The results of this work are used to identify the people, products, patterns of use, and regulatory policies that are most likely to encourage and assist smokers to switch to vaping, and to advise against the adoption of regulations and legislation that may reduce the accessibility, affordability, appeal and effectiveness of e-cigarettes as a way of quitting smoking.

  • Mitch Zeller, J.D.

    Director, Center for Tobacco Products FDA

    Mitch Zeller, J.D., became director of the U.S. Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP) in March 2013. The mission of CTP—established by enactment of the 2009 Family Smoking Prevention and Tobacco Control Act—is “to make tobacco-related death and disease part of America’s past, not America’s future, and, by doing so, ensure a healthier life for every American family.”

    “Today, FDA has an unprecedented opportunity to use the new tools in the Tobacco Control Act,” Zeller said. “Product regulation is a powerful component of a comprehensive strategy to reduce the death and disease from tobacco use. We will marshal the science to support new policies to help combat the leading cause of preventable disease and death in the United States,” he added.

    Mr. Zeller, a graduate of Dartmouth College and the American University Washington College of Law, has been working on FDA issues for more than 30 years. He began his career as a public interest attorney in 1982 at the Center for Science in the Public Interest (CSPI). In 1988, Mr. Zeller left CSPI to become counsel to the Human Resources and Intergovernmental Relations Subcommittee of the House of Representatives Government Operations Committee where he conducted oversight of enforcement of federal health and safety laws.

    Mr. Zeller joined the staff of then FDA Commissioner David Kessler, M.D., in 1993. What began as a two-week assignment by Kessler to examine the practices of the tobacco industry led to his serving as associate commissioner and director of FDA’s first Office of Tobacco Programs. Instrumental in crafting the agency’s 1996 tobacco regulations, Mr. Zeller also represented FDA before Congress, federal, and state agencies. Mr. Zeller also served as an official U.S. delegate to the World Health Organization (WHO) Working Group for the Framework Convention on Tobacco Control.

    In 2000, Mr. Zeller left the FDA to continue his work for tobacco control as executive vice president of the American Legacy Foundation. His responsibilities there included marketing, communications, strategic partnerships, and, in 2002, creating the foundation's first Office of Policy and Government Relations. That year, Mr. Zeller joined Pinney Associates where, as senior vice president, he provided strategic planning and communications advice on domestic and global public health policy issues involving the treatment of tobacco dependence and the regulation of tobacco products and pharmaceuticals. 

    Mr. Zeller, who is also a professorial lecturer at American University School of Law, lives with his family in Montgomery County, Maryland.